Plné znění - 80/2017 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2017 - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

80/2017 Sb. m. s.

Sdělení

INFORMACE

80

SDĚLENÍ

Ministerstva zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x. x x. 46/2008 Xx. m. x.

 

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, že dne 28. xxxxxxxxx 2016 xxxx xxxxxxxxx ředitelkou XXXXXX oznámeno schválení xxxxxx znění Přílohy X (Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx xxx 2017 - Xxxxxxxxxxx xxxxxxxx) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X novým xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Parlament Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx znění Přílohy X xxxxxxxxx x xxxxxxxx v souladu x článkem 34 odst. 3 Úmluvy xxx 1. xxxxx 2017 x xxx Českou xxxxxxxxx vstoupilo x xxxxxxxx xxx 30. xxxxx 2017.

Xxxx vstupu xxxxxx xxxxx Přílohy X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X xxxxxx xx 1. xxxxx 2016, xxxxxxxxx pod č. 26/2017 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X a xxxx xxxxxxx xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.

XXXXXXX ANTIDOPINGOVÝ KODEX

SEZNAM XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2017

XXXXXXXXXXX STANDARD

Oficiální xxxx Xxxxxxx xxxx xxxxxxxxx XXXX a xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx konfliktů xxxx xxxxxxxxx x xxxxxxxxxxxx verzí xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx platný xx 1. ledna 2017 

XXXXXX ZAKÁZANÝCH XXXXX X XXXXX DOPINGU XXX XXX 2017

SVĚTOVÝ XXXXXXXXXXXXX KODEX

Platný xx 1. xxxxx 2017

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx za "Xxxxxxxxxx xxxxx" kromě látek xx skupin S1, X2, S4.4, S4.5 x X6(x) x Xxxxxxxxxx metod M1, X2 a X3.

XXXXX X METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx farmakologicky xxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx stadiu výzkumu xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx schválené xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX LÁTKY

Anabolické xxxxx xxxx zakázány.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (XXX):

(x) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17ß-ol);

gestrinon;

4-hydroxytestosteron (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-hydroxy-2α,17α-dimethyl-5α-androstan-3-on);

methyldienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** AAS, xxxxx jsou podány xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxxxx-3xx); 

xxxxxxxxx (19-xxxxxxxxxxxxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (dehydroepiandrosteron, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx x xxxxxxx, xxx ne x xxxxxxxx pouze xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx anabolické xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, xxxx. xxxxxxx a xxxxxxx); xxxxxxx; xxxxxxx x xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x látce, xxxxxx tělo normálně xxxxxxxxx neprodukuje. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX X MIMETIKA

Následující xxxxx x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx:

1.1 Xxxxx xxxxxxxxxxx xxxxxxxxxxx (XXX) xxxxxx xxxx.

xxxxxxxxxxxx (dEPO);

erytropoetinů (XXX);

XXX-Xx;

XXX-xxxxxxxxxxx xxxxxxx (EMP), xxxx. XXXX 530 x xxxxxxxxxxx;

xxxxxxxxxx XXXX, xxxx. X-11706;

xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX);

xxxxxxxxxx transformujícího xxxxxxxxx xxxxxxx beta (XXX-xxxx), xxxx. xxxxxxxxxxx, xxxxxxxxxxxx;

1.2 Xxxxxxxx neerytropoetického XXX xxxxxxxxx, např.

ARA-290;

asialo EPO;

karbamylovaný XXX;

2. Xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxx. kobalt, xxxxxxxxxx x roxadustat (FG-4592); x aktivátory XXX, xxxx. xxxxx x xxxxx.

3. Xxxxxxxxxxxxxxxxxx (XX) x luteinizační xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx, např. xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx, x mužů.

4. Xxxxxxxxxxxxxx a jejich xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx.

5. Růstový xxxxxx (XX) x jeho xxxxxxxxxx xxxxxxx včetně: xxxxxxx xxxxxxxxxxxx růstový xxxxxx (GHRH) a xxxx xxxxxxx, xxxx. XXX-1295, xxxxxxxxxxx x xxxxxxxxxxxx; sekretagogů xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxxx a xxxxxxx xxxxxxxx, xxxx. anamorelinu x xxxxxxxxxxx; xxxxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxxx, XXXX-6, hexarelinu x xxxxxxxxxxxx (XXXX- 2).

Xxxxx xxxx jsou xxxxxxxx xxxxxxxxxxx xxxxxxx faktory:

Fibroblastové xxxxxxx xxxxxxx (FGFs); xxxxxxxxxxxx xxxxxxx faktor (XXX); xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1) x jeho xxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxx (XXX); růstový xxxxxx xxxxxxxx x krevních xxxxxxxx (PDGF); xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF), xxxxxx jako jakékoliv xxxx růstové faktory xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx zásobení, xxxxxxx xxxxxxx, regenerativní xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx vláken.

S3. BETA2- XXXXXXXX

Xxxxxxx selektivní x xxxxxxxxxxxx xxxx2- xxxxxxxx, xxxxxx všech xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; formoterol; higenamin; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx, nepřekročit 800 xxxxxxxxxx za každých 12 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx dodaná dávka 54 xxxxxxxxxx za 24 hodin;
• inhalační salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx vyšší xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 40 ng/ml nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx způsoben xxxxxxxx xxxxxxxxxxxx dávky (x xxxxxxxx) xxxxx, xxx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx modulátory:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-oxo);

exemestan;

formestan;

letrozol;

testolacton,

ale ne x xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

tamoxifen;

toremifen, xxx xx x xxxxxxxx xxxxx xx xx.

3. Ostatní xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx; xxxxxxxxxxx x klomifen, xxx xx x omezením xxxxx xx xx.

4. Xxxxx modifikující funkci(e) xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx

x xxxxxxxx pouze xx xx.

5. Metaboiické xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. AICAR; x Agonisté Xxxxxxxxx xxxxx aktivovaného xxxxxxxxxxxxxx xxxxxxxxxxxxx (PPARδ), xxxx. XX 1516;

5.2 Xxxxxxxx x xxxxxxxx insulinů;

5.3 Xxxxxxxxx;

5.4 Trimetazidin.

S5. XXXXXXXXX X MASKOVACÍ XXXXX

Xxxxxxxxxxx xxxxxxxxx a maskovací xxxxx jsou xxxxxxxx, xxxxxx xxxx xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), probenecid, xxx xx x omezením xxxxx xx ně.

• Acetazolamid, xxxxxxxx, xxxxxxxxx, furosemid, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, chlorothiazid), xxxxxxxxxx x vaptany (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx na xx.

X xxxxxxxx:

• xxxxxxxxxxxx, xxxxxxxxx x xxxxxx xxxxxx inhibitorů xxxxxxxxxxxxxx (např. xxxxxxxxxxx x brinzolamidu)

• Lokálního podání xxxxxxxxxxxx xxx zubní xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx limitem (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) ve Xxxxxx Xxxxxxxxx xxxxxxxx xxxx

xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx látku xxxxx x té, xxxxx xxx byla xxxxxxx xx diuretikum xxxx xxxxx maskovací látku.

ZAKÁZANÉ XXXXXX

X1. XXXXXXXXXX X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx autologní, xxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx krvinek x xxx xxxxxxxxx produktů xxxxxxxxxxx xxxxxx do xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx produkty (xxxx. xxxxxx náhražky založené xx xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx xxxxx na xx. Xxxxxxxxx suplementace xxxxxxxx zakázána xxxx.

3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx následující:

1. Xxxxxxxxx, xxxx Pokus o Xxxxxx, xx účelem xxxxxxx xxxxxxxxx a xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx s xxxxxxxx xxxxx xx ně.

2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxx 50 ml xx 6 xxxxx kromě xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.

X3. GENOVÝ DOPING

Z xxxxxx xxxxxxxxxx xx xxxxxxx sportovního xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx jejich xxxxxxx;

2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX A XXXXXX XXXXXXXX PŘI SOUTĚŽI

Kromě xxxxxxxxx X0 xx X5 x X1 xx M3 uvedených xxxx

xxxx Xxx Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. STIMULANCIA

Všechna xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx optických xxxxxxx, xxxx. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx /4-fenylpiracetam (karfedon)/,

furfenorex,

klobenzorex,

kokain,

kropropamid,

krotetamid,

lisdexamfetamin,

mefenorex,

mefentermin,

metamfetamin (x-),

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxxx, 

x-xxxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx není xxxxxxxx xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx látkou.

(b) Specifická xxxxxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx pouze xx xx):

Xxxxxxxxx (xxxxxxxxx)****,

xxxxxxxxxxx,

xxxxxxxxxxxxxxxxx,

xxxxxxx***,

xxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx x jeho xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxx,

xxxxx**,

xxxxxxx x jeho xxxxxxx (xxxx. mefedron, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxxxx***,

xxxxxxxxxxxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx),

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxx (xxxxxxxxxxxxx),

xxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxxx,

xxxxxxxxxxxxx*****,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx (metylendioxyamfetamin),

tuaminoheptan

a xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X výjimkou:

• klonidinu

• derivátů imidazolu x xxxxxxx jejich xxxxxxxx/xxxxxx použití a xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx programu xxx xxx 2017*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2017 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: xx zakázaný xxxxx xxx koncentraci xxxxx než 5 xxxxxxxxxx v 1 xx xxxx.

*** Xxxxxxx x methylefedrin: jsou xxxxxxxx při koncentraci xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): není xxxxxxx xxx xxxxxxxx podání, xxxx. nosní, xxxx xxxxxxxx xxxx xxxx xxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx.

***** Pseudoefedrin: xx zakázán, pokud xxxx koncentrace x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx mililitr.

S7. NARKOTIKA

Zakázané xx xxxxxxxxxxx:

Xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx(xxxxxx),

xxxxxxxx x xxxx xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

• Xxxxxxxx (xxxx. xxxxx, konopí a xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX).

• Xxxxxxxxxxxxxx, např. "Xxxxx", XXX018, JWH073 x XX-210.

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

XXXXX ZAKÁZANÉ V URČITÝCH XXXXXXXX

X1. ALKOHOL

Alkohol (etanol) xx zakázaný pouze Xxx Xxxxxxx x xxxxxxxxxxxxx sportech. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx zkouškou a/nebo xxxxxxxx xxxx. Prahová xxxxxxx xxx porušení xxxxxxxxxxx pravidla xx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x krvi 0,10 x/x.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxxxxx (XX)

• Xxxxxxx xxxxxx x xxxxxxxxxxxx (FAI)

• Vodní motorismus (XXX)

X2. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, x xxx xx xx xxxxxxxx x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)

• Golf (IGF)

• Lukostřelba (XX)*

• Xxxxxxxx (FIS) - xxxxx na lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, a xxxxxxxxx U-rampa a "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (CMAS) x disciplínách xxxxxxxxxx xxxx s ploutvemi xxxx bez ploutví, xxxxxxxxx apnoe x xxxxxxxxx xxxx xxx xxxxxxx, free immersion, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, střelba xxxxxxxx xx terč x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxx, 

xxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxxx,

xxx ne x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx č. 80/2017 Xx. m. x. nabyl xxxxxxxxx xxxx 4.1.2018.

Právní xxxxxxx x. 80/2017 Sb. x. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 36/2019 Sb. m. s. x xxxxxxxxx xx 26.7.2019.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx není xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx derogační změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx úmluva xxxxx xxxxxxx ve xxxxxx, xxxxxxx dne 19. xxxxx 2005 x Paříži, xxxx xxxxxxxxx x xxxxxxxxx xxxxx x s xxxxxxxxx xx českého xxxxxx xxx č. 58/2007 Sb. m. s.

Nové xxxxx xxxxxxxx Xxxxxx xx xxxxxxx xxxxxx xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.